Tempus AI to Acquire Personalis for $1.5 Billion, Adding MRD-Based Cancer Test to Precision Oncology Portfolio
核心洞察
Tempus AI announced a definitive agreement to acquire cancer (搜索) test maker Personalis in a deal valued at approximately $1.5 billion, paid primarily in Tempus stock.
The acquisition centers on Personalis' NeXT Personal (搜索) test, which uses minimal residual disease (MRD) technology to detect trace amounts of cancer (搜索) after treatment via personalized genetic signatures.
Personalis shareholders will receive $16.25 per share, representing a 5.6% premium to the last closing price, with Tempus retaining the option to pay up to 50% in cash.
Tempus AI said on Monday it would acquire Personalis in a deal valued at approximately $1.5 billion, a move that adds a sophisticated cancer (搜索) detection test to the AI-enabled precision medicine company's oncology portfolio. The announcement, reported by Reuters on July 20, sent shares of both companies lower in morning trading, with Personalis falling 12% and Tempus dropping nearly 9%.
Under the terms of the agreement, Personalis shareholders will receive $16.25 per share, primarily in Tempus stock, representing a 5.6% premium to the cancer (搜索) test maker's last closing price. Tempus retains the option to pay up to 50% of the deal value in cash. The stock-based structure contributed to the share price declines, according to Guggenheim analyst Subbu Nambi, who noted that Personalis investors remain skeptical about Tempus' potential upside.
The NeXT Personal (搜索) Test: MRD Technology at the Core
The acquisition gives Tempus access to Personalis' NeXT Personal (搜索) cancer (搜索) test, a platform built on minimal residual disease (MRD) technology. MRD testing is designed to detect tiny traces of cancer that may remain after surgery, chemotherapy, or other treatments — traces that can be too small to appear on conventional imaging scans.
The NeXT Personal (搜索) test works by creating a personalized genetic signature of a patient's cancer (搜索). Physicians can then track this signature over time through blood tests, enabling longitudinal monitoring for residual or recurrent disease. This approach represents a growing area of interest in oncology, where early detection of recurrence can meaningfully impact clinical decision-making.
Building on an Existing Partnership
The acquisition is not the first collaboration between the two companies. Tempus invested in Personalis in November 2023 as part of a partnership to co-develop the NeXT Personal (搜索) test. That earlier investment laid the groundwork for the full acquisition now underway.
Tempus CEO Eric Lefkofsky addressed the timing of the deal, stating, "The reason we didn't do this a year or two ago is we wanted to be at the point in the curve where this was going to quickly turn into a really healthy business from a gross profit and a margin perspective."
The transaction is expected to close in late 2026 or early 2027, subject to customary closing conditions and regulatory approvals. Once completed, the combined entity aims to strengthen its position in the precision oncology space by integrating AI-driven insights with advanced MRD-based cancer (搜索) monitoring.